Radiotherapy Market to be Worth $17.86 Billion by 2030
o
Radiotherapy
Market to be Worth $17.86 Billion by 2030
|
Meticulous Research®—a leading global
market research company, published a research report titled, ‘Radiotherapy Market by Product (Devices
[LINAC, Gamma Knife, CyberKnife, Cyclotron, Synchrotron, Brachytherapy],
Services, Software), Technology (IMRT, IGRT, 3D-CRT, Proton Beam Therapy,
PDR-BT), Cancer (Breast, Prostate, Lung) - Global Forecast to 2030.’
Download Free Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5023
According to this latest publication from
Meticulous Research®, the radiotherapy market is projected to reach $17.86 billion by
2030, at a CAGR of 8.4% during the forecast period. The growth of this market
is driven by the rising cancer incidence rate, technological advancements in
the field of radiotherapy, growing awareness about the benefits of
radiotherapy for cancer treatment, growing healthcare expenditure, and rising
use of particle therapy for cancer treatment. However, the high cost and
complexities associated with radiotherapy procedures, lack of advanced
infrastructure facilities, and lack of skilled healthcare professionals are
restraining the market’s growth.
Furthermore, the high growth prospects in
emerging economies and rising investments by public and private organizations
in Cancer Research are expected to offer significant market growth
opportunities. However, the difficulties in visualizing tumors during
radiotherapy procedures and the risks associated with radiation exposure are
the major challenge to the market’s growth.
The key players operating in the radiotherapy
market are Siemens Healthineers AG (Germany), Elekta AB (Sweden), Accuray
Incorporated (U.S.), IBA (Belgium), Mevion Medical Systems, Inc. (U.S.),
Hitachi, Ltd. (Japan), ViewRay Technologies, Inc. (U.S.), Panacea Medical
Technologies Pvt. Ltd. (India), IsoRay, Inc. (U.S.), Optivus Proton Therapy,
Inc. (U.S.), and P-Cure, Ltd. (Israel).
Radiotherapy Market: Future
Outlook
The radiotherapy market is segmented based on
Product [Radiotherapy Devices {External Beam Radiotherapy Systems,
(Conventional Linear Accelerators, Conventional Co-60 Teletherapy Units,
Advanced Stereotactic Radiotherapy Systems (Gamma Knife, CyberKnife,
TomoTherapy), Proton Beam Therapy Systems/Particle Beam Therapy Systems
(Cyclotron, Synchrotron, Synchrocyclotron), Internal Beam Radiotherapy
Systems/Brachytherapy Systems (Electronic Brachytherapy Products,
Afterloaders)}, Radiotherapy Consumables and Accessories, Services, Software],
Technology [External Beam Radiotherapy {Intensity Modulated Radiation Therapy
(IMRT), Image Guided Radiation Therapy (IGRT), Stereotactic Radiation Therapy
(SRT), 3D Conformal Radiation Therapy (3D-CRT), Proton Beam Therapy/ Particle
Beam Therapy}, Internal Beam Radiotherapy [Brachytherapy {High Dose Rate
Brachytherapy, Low Dose Rate Brachytherapy, Image Guided Brachytherapy, Pulse
Dose Rate Brachytherapy}, Systemic Radiation Therapy {Intravenous
Radiotherapy, Oral Radiotherapy}], Cancer Type [Breast Cancer, Prostate
Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Cervical
Cancer], and Geography. The study also evaluates industry competitors and
analyzes the market at the regional and country levels.
Speak to analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5023
Based on type, in 2023, the
radiotherapy devices segment is expected to account for the largest share of
the radiotherapy market. High adoption of advanced radiotherapy devices such
as CyberKnife and Gamma Knife and higher pricing of these devices over
accessories, software, and services are the key factors supporting the
segment’s largest share in the market. The key market players are continuously
focused on developing and launching new technologies. For instance, in June
2020, Accuray Incorporated (U.S.) launched the CyberKnife system tracks and
synchronizes treatment delivery for all stereotactic radiosurgery (SRS) and
stereotactic body radiation therapy (SBRT) treatments within 15 minutes.
Based on technology, in 2023, the
external beam radiotherapy segment is expected to account for the largest
share of the radiotherapy market. External beam radiation therapy produces
radiations that are used outside the body and has the benefits such as
coverage of large areas of the body and high accuracy and precision of cancer
cell targeting. External beam radiation treats various types of cancers, such
as colorectal cancer, prostate cancer, breast cancer, and lung cancer.
Based on cancer type, in 2023, the
prostate cancer segment is expected to account for the largest share of the
radiotherapy market. The largest market share of this segment is attributed to
the high incidence of prostate cancer coupled with the development of newer
approaches in radiotherapy for treating prostate cancer. In March 2022, U.S.
Food and Drug Administration (FDA) approved Novartis Pluvicto as the first
target radioligand therapy for treating progressive, prostate-specific
membrane antigen–positive metastatic castration-resistant prostate cancer
(PSMA-positive mCRPC) in adults.
This research report analyzes major
geographies and provides a comprehensive analysis of North America (U.S. and
Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe),
Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America
(Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa.
In 2023, North America is expected to account for the largest share of the
radiotherapy market, followed by Europe and Asia-Pacific. Furthermore, in
2023, the U.S. is expected to be the largest market shareholder in North
America. The market growth in the U.S. is attributed to the high healthcare
expenditure for cancer, highly developed healthcare infrastructure, the
presence of key cancer radiotherapy developing companies such as Accuray
Incorporated (U.S.) and Mevion Medical Systems, Inc. (U.S.), and government
programs supporting early cancer screening.
Quick Buy: https://www.meticulousresearch.com/Checkout/54759092
Key questions answered in
the report:
· Which are
the high-growth market segments in terms of product, technology, cancer type,
and region/country?
· What was
the historical market size for radiotherapy across the globe?
· What are
the market forecasts and estimates for the period 2023–2030?
· What are
the major drivers, restraints, and opportunities in the global radiotherapy
market?
· Who are
the major players in the global radiotherapy market?
· How is the
competitive landscape, and who are the market leaders in the global
radiotherapy market?
· What are
the recent developments in the radiotherapy market?
· What are
the different strategies adopted by the major players in the radiotherapy
market?
· What are
the geographical trends and high growth regions/countries?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous- research
Comments
Post a Comment